http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017123156-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_266f27c9e90e00b1173c45726524c540
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dded61bd89f99900518597c0958b9a9
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-32
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-32
filingDate 2017-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_125dd28640a6dbf63f795064b638da09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0003d5ddc1e3d96677860b5670173fdf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_271ce726eee83e5fb6a84614ec18c6e7
publicationDate 2017-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2017123156-A1
titleOfInvention Crystalline forms of olaparib and manufacturing processes therefor
abstract In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4- cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2 H )phthalazin- 1 -one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022090938-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022058785-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111718300-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020531522-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10703728-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023084311-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10662178-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021220120-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022215034-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023017393-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10138211-B2
priorityDate 2016-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009050469-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008047082-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015284416-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105439961-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014206389-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID87410937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228690799
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226457726
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24811740
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23725625
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226751264

Total number of triples: 39.